ME02944B - Novo antitelo protiv humanog ngf - Google Patents
Novo antitelo protiv humanog ngfInfo
- Publication number
- ME02944B ME02944B MEP-2018-28A MEP201828A ME02944B ME 02944 B ME02944 B ME 02944B ME P201828 A MEP201828 A ME P201828A ME 02944 B ME02944 B ME 02944B
- Authority
- ME
- Montenegro
- Prior art keywords
- fragment
- fab
- human ngf
- against human
- antibody against
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 25
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims 8
- 102000046917 human NGF Human genes 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 230000021615 conjugation Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- -1 polyethylen Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011176209 | 2011-08-11 | ||
| JP2011269215 | 2011-12-08 | ||
| PCT/JP2012/070433 WO2013022083A1 (ja) | 2011-08-11 | 2012-08-10 | 新規抗ヒトｎｇｆ抗体 |
| EP12821758.5A EP2743348B1 (en) | 2011-08-11 | 2012-08-10 | Novel anti-human ngf antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02944B true ME02944B (me) | 2018-04-20 |
Family
ID=47668585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2018-28A ME02944B (me) | 2011-08-11 | 2012-08-10 | Novo antitelo protiv humanog ngf |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8986952B2 (enExample) |
| EP (1) | EP2743348B1 (enExample) |
| JP (1) | JP5376095B2 (enExample) |
| KR (1) | KR101999867B1 (enExample) |
| CN (1) | CN103748222B (enExample) |
| AR (1) | AR087506A1 (enExample) |
| AU (1) | AU2012293161B2 (enExample) |
| BR (1) | BR112014002576B1 (enExample) |
| CA (1) | CA2841181C (enExample) |
| CY (1) | CY1119914T1 (enExample) |
| DK (1) | DK2743348T3 (enExample) |
| EA (1) | EA024292B1 (enExample) |
| ES (1) | ES2663968T3 (enExample) |
| HR (1) | HRP20180155T1 (enExample) |
| HU (1) | HUE036079T2 (enExample) |
| IL (1) | IL230797A (enExample) |
| IN (1) | IN2014CN00614A (enExample) |
| LT (1) | LT2743348T (enExample) |
| ME (1) | ME02944B (enExample) |
| MX (1) | MX351273B (enExample) |
| NO (1) | NO2743348T3 (enExample) |
| PH (1) | PH12014500001A1 (enExample) |
| PL (1) | PL2743348T3 (enExample) |
| PT (1) | PT2743348T (enExample) |
| RS (1) | RS56876B1 (enExample) |
| SI (1) | SI2743348T1 (enExample) |
| SM (1) | SMT201800166T1 (enExample) |
| TW (1) | TWI554519B (enExample) |
| WO (1) | WO2013022083A1 (enExample) |
| ZA (1) | ZA201400741B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| WO2012075340A2 (en) | 2010-12-01 | 2012-06-07 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| BR112017025029A2 (pt) * | 2015-05-22 | 2018-08-07 | Astellas Pharma Inc. | ?novo fragmento fab de anticorpo ngf anti- humano?. |
| JPWO2017164349A1 (ja) * | 2016-03-25 | 2019-02-07 | アステラス製薬株式会社 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
| CN114751982B (zh) * | 2017-12-15 | 2023-06-23 | 安源医药科技（上海）有限公司 | 抗人ngf抗体及其制备方法和用途 |
| US20210147529A1 (en) | 2018-05-15 | 2021-05-20 | Astellas Pharma Inc. | Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| KR100337069B1 (ko) * | 1993-03-11 | 2002-10-11 | 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 | 항-hiv모노클로날항체 |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN1684708A (zh) | 2001-05-30 | 2005-10-19 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| CN101014364B (zh) | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| EA013614B1 (ru) | 2003-07-15 | 2010-06-30 | Амджен Инк. | Изолированное антитело к фактору роста нервов (ngf) и способы его применения |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| NZ556157A (en) | 2005-01-24 | 2009-09-25 | Elan Pharma Int Ltd | Specific binding members for NGF |
| RS53661B1 (sr) * | 2007-08-10 | 2015-04-30 | Regeneron Pharmaceuticals, Inc. | Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| RU2461551C2 (ru) | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль |
| US8435523B2 (en) | 2009-05-04 | 2013-05-07 | Abbott Research B.V. | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
-
2012
- 2012-08-10 PT PT128217585T patent/PT2743348T/pt unknown
- 2012-08-10 SI SI201231222T patent/SI2743348T1/en unknown
- 2012-08-10 AU AU2012293161A patent/AU2012293161B2/en not_active Ceased
- 2012-08-10 PL PL12821758T patent/PL2743348T3/pl unknown
- 2012-08-10 BR BR112014002576-2A patent/BR112014002576B1/pt not_active IP Right Cessation
- 2012-08-10 SM SM20180166T patent/SMT201800166T1/it unknown
- 2012-08-10 LT LTEP12821758.5T patent/LT2743348T/lt unknown
- 2012-08-10 US US13/879,267 patent/US8986952B2/en active Active
- 2012-08-10 NO NO12821758A patent/NO2743348T3/no unknown
- 2012-08-10 KR KR1020147003155A patent/KR101999867B1/ko not_active Expired - Fee Related
- 2012-08-10 RS RS20180173A patent/RS56876B1/sr unknown
- 2012-08-10 CN CN201280039293.3A patent/CN103748222B/zh not_active Expired - Fee Related
- 2012-08-10 CA CA2841181A patent/CA2841181C/en active Active
- 2012-08-10 HR HRP20180155TT patent/HRP20180155T1/hr unknown
- 2012-08-10 EA EA201490433A patent/EA024292B1/ru not_active IP Right Cessation
- 2012-08-10 TW TW101128963A patent/TWI554519B/zh not_active IP Right Cessation
- 2012-08-10 JP JP2013525474A patent/JP5376095B2/ja not_active Expired - Fee Related
- 2012-08-10 AR ARP120102927 patent/AR087506A1/es active IP Right Grant
- 2012-08-10 WO PCT/JP2012/070433 patent/WO2013022083A1/ja not_active Ceased
- 2012-08-10 ME MEP-2018-28A patent/ME02944B/me unknown
- 2012-08-10 EP EP12821758.5A patent/EP2743348B1/en active Active
- 2012-08-10 DK DK12821758.5T patent/DK2743348T3/en active
- 2012-08-10 IN IN614CHN2014 patent/IN2014CN00614A/en unknown
- 2012-08-10 HU HUE12821758A patent/HUE036079T2/hu unknown
- 2012-08-10 ES ES12821758.5T patent/ES2663968T3/es active Active
- 2012-08-10 PH PH1/2014/500001A patent/PH12014500001A1/en unknown
- 2012-08-10 MX MX2014001627A patent/MX351273B/es active IP Right Grant
-
2014
- 2014-01-30 ZA ZA2014/00741A patent/ZA201400741B/en unknown
- 2014-02-03 IL IL230797A patent/IL230797A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/596,874 patent/US20150218265A1/en not_active Abandoned
-
2018
- 2018-02-14 CY CY20181100180T patent/CY1119914T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02944B (me) | Novo antitelo protiv humanog ngf | |
| CY1121802T1 (el) | Μεθοδοι αγωγης της αγκυλοποιητικης σπονδυλιτιδας με τη χρηση αντισωματων anti-il-17 | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| HRP20190752T1 (hr) | Novo protutijelo protiv ljudskog receptora tslp | |
| NZ607969A (en) | Cd33 binding agents | |
| EA035160B9 (ru) | Антитела к st2 и их применение | |
| NZ722585A (en) | Targeted/immunomodulatory fusion proteins and methods for making same | |
| ES2584956T3 (es) | Anticuerpos anti-CD40 y usos de los mismos | |
| NZ703653A (en) | Anti-fap antibodies and methods of use | |
| NZ600470A (en) | Anti-c4.4a antibodies and uses thereof | |
| NZ603226A (en) | Anti-c5a antibodies and methods for using the antibodies | |
| MX356367B (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. | |
| NZ706004A (en) | Antibodies for treatment of cancer expressing claudin 6 | |
| NZ597692A (en) | Anti-IGF antibodies | |
| NZ630847A (en) | Anti-sema4d antibodies and epitopes | |
| ES2721753T3 (es) | Anticuerpos contra IL-6 y usos de los mismos | |
| MX359384B (es) | Conjunto mejorado de anticuerpos bisespecificos. | |
| PE20140979A1 (es) | Variantes de fc silenciosas de los anticuerpos anti-cd40 | |
| NZ610091A (en) | Antibodies | |
| WO2013054331A8 (en) | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) | |
| NZ723229A (en) | Immunogens for hiv vaccination | |
| AR075849A1 (es) | Moleculas de anticuerpos que tienen especificidad de union por il-13 humana | |
| MX2016008520A (es) | Anticuerpo bdca-2 antihumano novedoso. | |
| WO2012162565A3 (en) | Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions | |
| NZ607615A (en) | Antibodies directed against il-17 |